進行性または転移性固形腫瘍の参加者におけるLY4050784の研究
SMARCA4/BRG1変異を伴う進行固形腫瘍悪性腫瘍における選択的SMARCA2/BRM阻害剤LY4050784の非盲検多施設研究
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Santa Monica、California、アメリカ、90404
- UCLA
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado Health Hospital
-
Denver、Colorado、アメリカ、80218
- Sarah Cannon Research Institute at HealthOne
-
-
Florida
-
Lake Mary、Florida、アメリカ、32746
- Florida Cancer Specialists ORLANDO/DDU
-
Miami、Florida、アメリカ、33136
- University of Miami
-
-
Illinois
-
New Lenox、Illinois、アメリカ、60451
- University of Chicago
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana-Farber Cancer Institute
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital
-
-
New York
-
New York、New York、アメリカ、10032
- Columbia University Medical Center
-
New York、New York、アメリカ、10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Hospital
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- Sarah Cannon Research Institute
-
Nashville、Tennessee、アメリカ、37232-6307
- Vanderbilt-Ingram Cancer Center
-
Nashville、Tennessee、アメリカ、37203
- SCRI Oncology Partners
-
-
Texas
-
Houston、Texas、アメリカ、77030-4009
- MD Anderson Cancer Center
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- USO-Virginia Cancer Specialists, PC
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- Medical College of Wisconsin
-
-
-
-
-
Barcelona、スペイン、08035
- Hospital Universitari Vall d'Hebron
-
Madrid、スペイン、28040
- South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
-
-
-
-
-
Berlin、ドイツ、10117
- Charite-Universitatsmedizin Berlin
-
Essen、ドイツ、45147
- Universitaetsklinikum Essen
-
Frankfurt am Main、ドイツ、60488
- Krankenhaus Nordwest
-
-
-
-
-
Bordeaux、フランス、33 076
- Institut Bergonie
-
Paris、フランス、75248
- Institut Curie
-
Villejuif、フランス、94800
- Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP
-
-
-
-
-
Chūōku、日本、104-0045
- National Cancer Center Hospital
-
Kashiwa、日本、277-8577
- National Cancer Center Hospital East
-
Kōtō City、日本、135-8550
- The Cancer Institute Hospital of JFCR
-
Nagaizumi-cho,Sunto-gun、日本、411-8777
- Shizuoka Cancer Center
-
-
-
-
-
Ilsandong-gu、韓国、10408
- National Cancer Center
-
Seoul、韓国、03722
- Severance Hospital, Yonsei University Health System
-
Suwon、韓国、16247
- The Catholic University of Korea, St. Vincent's Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Have one of the following locally advanced or metastatic solid tumor malignancy with SMARCA4 (BRG1) alteration:
- Phase 1a dose escalation: Presence of any alteration in SMARCA4 (BRG1)
- Phase 1b expansion: Part A: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
- Phase 1b expansion: Part B: Any tumor type (other than NSCLC) that has the presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
- Phase 1b expansion: Part C: Non-small Cell Lung Cancer (NSCLC) that is locally advanced and not suitable for definitive locoregional therapy, or metastatic with presence of a known or likely loss of function alteration in SMARCA4 (BRG1) or loss of protein expression.
-
Prior Systemic Therapy Criteria:
- Phase 1a dose escalation and Phase 1b (Part B): Participants who received all standard therapies for which the individual was deemed to be an appropriate candidate by the treating Investigator; or the individual is refusing the remaining most appropriate standard of care treatment; or there is no standard therapy available for the disease.
- Phase 1b expansion (Part A): Participants must have received at least one line of therapy for advanced or metastatic disease.
- Phase 1b expansion (Part C): Participants may be treatment naïve or have received therapy for advanced or metastatic disease
-
Measurability of disease
- Phase 1a dose escalation (excluding backfill): measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)
- Phase 1a backfill and Phase 1b expansion: Measurable disease required as defined by RECIST v1.1
-
Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Exclusion Criteria:
- Participants with known or likely loss of function alteration of SMARCA2 (BRM) or malignancy with known association with SMARCA2 (BRM) alterations
- Prior exposure to SMARCA2 (BRM) inhibitor(s) and/or degrader(s) (prior exposure may be permitted for dose escalation)
- Participants with known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement
- Participants with history of increased risk of prolonged QT or significant arrythmia
- Significant cardiovascular disease
- Participants with active and/or treated for an additional primary malignancy within 2 years prior to enrolment
- Participants who are pregnant, breastfeeding or plan to breastfeed or expecting to conceive or father children during study or within 6 months after the last dose of study intervention
- Participants with history of active autoimmune diseases, history of allogenic stem cell/organ transplant or compromised immune system within past 2 years (Part C only)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:LY4050784 (Phase 1a - Dose Escalation)
Escalating doses of LY4050784 administered orally. |
Oral |
|
実験的:LY4050784 (Phase 1b - Dose Optimization/Part A)
Comparing 2 or more doses (evaluated during dose escalation) of LY4050784 administered orally. |
Oral |
|
実験的:LY4050784 (Phase 1b - Dose Expansion/Part B)
LY4050784 administered orally. |
Oral |
|
実験的:LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C1
LY4050784 administered orally in combination in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. |
|
実験的:LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2a
LY4050784 administered orally in combination in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. Administered IV. Administered IV. Administered IV. |
|
実験的:LY4050784 (Phase 1b - Dose Expansion/Part C) Cohort C2b
LY4050784 administered orally in combination in combination with pembrolizumab, paclitaxel/nab-paclitaxel and carboplatin administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met. |
Oral Administered IV. Administered IV. Administered IV. Administered IV. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Phase Ia: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs)
時間枠:Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1a: To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of LY4050784
時間枠:Up to Approximately 48 Months or 4 Years
|
Number of participants with dose-limiting toxicities (DLTs) |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b: To assess the antitumor activity of LY4050784 Monotherapy: Overall response rate (ORR)
時間枠:Up to Approximately 48 Months or 4 Years
|
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b (Dose optimization only): To confirm the RP2D/optimal dose based on safety and efficacy of LY4050784
時間枠:Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module, ORR and Duration of Response (DOR) per Investigator |
Up to Approximately 48 Months or 4 Years
|
|
Phase 1b (Combination cohorts/Part C): To assess the safety and tolerability of LY4050784 when administered in combination with other anticancer agents
時間枠:Up to Approximately 48 Months or 4 Years
|
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module |
Up to Approximately 48 Months or 4 Years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
併用コホートでLY4050784のPK特性を評価するには:最大濃度(CMAX)PK:LY4050784のCMAX:
時間枠:サイクル1(8日目)
|
サイクル1(8日目)
|
|
|
組み合わせコホートでLY4050784のPK特性を評価するには:最大濃度(TMAX)PK:LY4050784のTMAX:
時間枠:サイクル1(8日目)
|
サイクル1(8日目)
|
|
|
組み合わせコホートでLY4050784のPK特性を評価するには:濃度対時間曲線(AUC)の下の面積
時間枠:サイクル1(8日目)
|
サイクル1(8日目)
|
|
|
To characterize the pharmacokinetics (PK) properties of LY4050784: Maximum Concentration (Cmax)
時間枠:Cycle 1 (Day 8)
|
PK: Cmax of LY4050784 |
Cycle 1 (Day 8)
|
|
To characterize the PK properties of LY4050784: Time to Maximum Concentration (Tmax)
時間枠:Cycle 1 (Day 8)
|
PK: Tmax of LY4050784 |
Cycle 1 (Day 8)
|
|
To characterize the PK properties of LY4050784: Area under the concentration versus time curve (AUC)
時間枠:Cycle 1 (Day 8)
|
PK: AUC of LY4050784 |
Cycle 1 (Day 8)
|
|
Phase Ia: To evaluate the preliminary antitumor activity of LY4050784: Overall response rate (ORR)
時間枠:Up to Approximately 48 Months or 4 Years
|
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Duration of response (DOR)
時間枠:Up to Approximately 48 Months or 4 Years
|
DOR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Time to response (TTR)
時間枠:Up to Approximately 48 Months or 4 Years
|
TTR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Disease control rate (DCR)
時間枠:Up to Approximately 48 Months or 4 Years
|
DCR per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
|
To evaluate the preliminary antitumor activity of LY4050784: Progression free survival (PFS)
時間枠:Up to Approximately 48 Months or 4 Years
|
PFS per investigator assessed RECIST 1.1 |
Up to Approximately 48 Months or 4 Years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 病理学的プロセス
- 部位別新生物
- 新生物
- 気道疾患
- 組織型別の新生物
- 肺疾患
- 新生物、腺および上皮
- 気道腫瘍
- 胸部腫瘍
- 腫瘍性プロセス
- がん
- 新生物、扁平上皮細胞
- がん、気管支原性
- 気管支腫瘍
- 病理学的状態、徴候および症状
- 肺新生物
- がん、扁平上皮細胞
- 新生物転移
- がん、非小細胞肺
- 腺癌
- アミノ酸、ペプチド、およびタンパク質
- 有機化学物質
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- 無機化学物質
- 塩素化合物
- 窒素化合物
- 調整錯体
- グアニン
- ヒポキサンチン
- ピリノン
- プリン
- グルタミン酸
- アミノ酸、酸性
- アミノ酸
- アミノ酸、ジカルボン酸
- タキソイド
- シクロデカン
- Diterpenes
- ヘルスケアの経済学と組織
- プラチナ化合物
- 経済
- ペメトレキセド
- カルボプラチン
- パクリタキセル
- シスプラチン
- ペンブロリズマブ
- 税金
その他の研究ID番号
- 27191
- J5M-OX-JOXA (その他の識別子:Eli Lilly and Company)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。